ASCO 2022 Conference Coverage
Playback speed
10 seconds
Lecture Summary - ASCO 2022 Subgroup Analysis of Patients With No Prior Chemo in Phase 3 EMERALD Trial: Elacestrant vs. Investigator’s Choice of Endocrine Monotherapy for ER+/HER2 mBC
By
ASCO 2022 Conference Coverage
FEATURING
Virginia Kaklamani
By
ASCO 2022 Conference Coverage
FEATURING
Virginia Kaklamani
57 views
June 10, 2022
Comments 0
Login to view comments.
Click here to Login
Breast